CAH · XBRL financial data

Cardinal Health financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CAH's year ends in late June)

In millions of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Revenue	162,467	181,364	205,012	226,827	222,578	254,248
Cost of goods and services sold	155,689	174,819	198,123	219,413	214,410	244,474
Gross profit	6,778	6,545	6,889	7,414	8,168	9,774
Selling, general and administrative	4,533	4,557	4,834	5,000	5,382	6,132
Operating income (loss)	472	(596)	727	1,243	2,275	2,613
Interest expense	180	149	93	51	215	348
Other income (expense)	47	(16)	4	9	41	31
Income tax expense (benefit)	(289)	163	376	348	532	469
Net income (loss)	611	(933)	261	852	1,561	1,714
Earnings per share, basic USD per share	2.09	(3.35)	1.00	3.48	6.48	7.27
Earnings per share, diluted USD per share	2.08	(3.35)	1.00	3.45	6.45	7.23
Weighted average shares, basic millions of shares	292	279	261	245	241	236
Weighted average shares, diluted millions of shares	294	279	262	247	242	237

Fiscal years (CAH's year ends in late June)

In millions of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	3,407	4,717	4,043	5,133	3,874	4,856
Short-term investments	—	—	—	200	—	—
Inventory	14,594	15,636	15,940	14,957	16,831	17,297
Total current assets	31,048	32,935	33,833	34,884	36,373	38,753
Property and equipment, net	2,360	2,361	2,462	2,529	2,858	3,031
Right-of-use asset	460	457	435	475	758	991
Goodwill	7,989	5,855	4,609	4,725	9,691	11,442
Total assets	44,453	43,878	43,417	45,121	53,122	57,299
Accounts payable	23,700	27,128	29,813	31,759	34,713	38,283
Total current liabilities	27,624	30,550	33,706	35,640	38,897	43,904
Lease liability, non-current	374	388	375	400	654	861
Retained earnings (accumulated deficit)	1,205	(280)	(534)	(286)	783	2,009
Total stockholders' equity	1,791	(709)	(2,852)	(3,213)	(2,781)	(2,883)
Total liabilities and equity	44,453	43,878	43,417	45,121	53,122	57,299
Common shares outstanding (cover page) millions of shares	290	273	251	244	239	233

Fiscal years (CAH's year ends in late June)

In millions of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	611	(933)	261	852	1,561	1,714
Stock-based compensation	89	81	96	121	244	367
Depreciation and amortization	783	692	692	710	790	956
Net cash from operating activities	2,429	3,122	2,839	3,762	2,397	5,174
Purchases of property and equipment	400	387	481	511	547	649
Net cash from investing activities	(378)	567	(454)	(1,849)	(5,593)	(2,584)
Share repurchases	200	1,000	2,000	750	765	1,358
Dividends paid	573	559	525	499	494	491
Proceeds from long-term debt	—	—	—	1,140	2,900	1,000
Repayments of long-term debt	570	885	579	783	445	653
Net cash from financing activities	(1,317)	(2,463)	(3,051)	(847)	1,940	(1,602)
Net change in cash	636	1,310	(674)	1,057	(1,259)	982

SIC 5122 and related industry codes, similar size; rows marked “added: same SIC” fill a short list. Each row is the latest quarter reported.

How peers are chosen

SIC 5122 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Fewer than three companies fall in that range, so the list adds same-SIC (5122) companies nearest in public float, each marked “added: same SIC”.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Cardinal Health	4,856	year only	year only	232.6M	—	Q4 FY26 10-KJun 30, 2026
Cencora	2,815	84,755	2,654*	190.8M	—	Q3 FY26 10-QJun 30, 2026
McKesson	5,164	105,380	(220)	116.6M	—	Q1 FY27 10-QJun 30, 2026
Herbalifeadded: same SIC	409	1,350	151*	104.9M	—	Q3 FY26 10-QSep 30, 2026
Nu Skin Enterprisesadded: same SIC	190	320	11*	48.7M	—	Q2 FY26 10-QJun 30, 2026
DataMeds AIadded: same SIC	2.5	1.8	(2.9)*	3.1M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
Cosmos Healthadded: same SIC	1.8	19	(1.7)*	100.6M	1.1 quarters	Q2 FY26 10-QJun 30, 2026
Stemtechadded: same SIC	0.2	0.6	(0.1)*	3.0B	4.5 quarters	Q2 FY26 10-QJun 30, 2026
HWH Internationaladded: same SIC	1.5	0.1	0.5*	7.7M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.